Cargando…
The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers
Oncolytic viruses are generally designed to be cancer selective on the basis of a single genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and lac-Z transgenes that is designed to destroy...
Autores principales: | Parato, Kelley A, Breitbach, Caroline J, Le Boeuf, Fabrice, Wang, Jiahu, Storbeck, Chris, Ilkow, Carolina, Diallo, Jean-Simon, Falls, Theresa, Burns, Joseph, Garcia, Vanessa, Kanji, Femina, Evgin, Laura, Hu, Kang, Paradis, Francois, Knowles, Shane, Hwang, Tae-Ho, Vanderhyden, Barbara C, Auer, Rebecca, Kirn, David H, Bell, John C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321594/ https://www.ncbi.nlm.nih.gov/pubmed/22186794 http://dx.doi.org/10.1038/mt.2011.276 |
Ejemplares similares
-
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
por: Breitbach, Caroline J, et al.
Publicado: (2015) -
Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma
por: Lun, XueQing, et al.
Publicado: (2010) -
Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
por: Cousin, Sophie, et al.
Publicado: (2022) -
Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma
por: Kung, Che-Hsuan, et al.
Publicado: (2015) -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
por: Toulmonde, Maud, et al.
Publicado: (2022)